Radioimmunotherapy in mantle cell lymphoma.
Mantle cell lymphoma (MCL), though characterized by the chromosomal translocation t(11; 14) (q13; q32), is a heterogeneous disease. Often termed an aggressive lymphoma in the U.S., but included in indolent lymphoma trials in Europe, MCL is not curable with standard immuno-chemotherapy. There is no single standard initial therapy for this disease. Although standard lymphoma therapies yield high response rates, relapse is inevitable. Unmet needs in MCL include better induction therapy, consolidation treatments to prolong first remission and better therapeutic options for relapsed disease. In this review, we evaluate the role of radioimmunotherapy (RIT) in MCL, a novel strategy combining monoclonal antibodies with radioisotopes to deliver radiation directly to tumour tissue, both in the frontline and relapsed setting.
Fox Chase Cancer Center, 333 Cottman Avenue, PA 19111, USA. Alan.Skarbnik@fccc.edu
Alan P
AP
Skarbnik
Mitchell R
MR
Smith
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy / Q000276:immunology / Q000532:radiotherapy*; D058990:Molecular Targeted Therapy / Q000379:methods*; D016499:Radioimmunotherapy / Q000379:methods*; D011868:Radioisotopes; D012008:Recurrence; D012074:Remission Induction
D000911:Antibodies, Monoclonal; D011868:Radioisotopes; C422802:ibritumomab tiuxetan; C119496:tositumomab I-131